FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:1491-1494 April 8, 2004 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Brousseau, M. E. PubMed Citation

In the past decade, high-density lipoproteins (HDL) have emerged as a new potential therapeutic target for the treatment of cardiovascular disease. The key role of HDL as a carrier of excess cellular cholesterol in the reverse cholesterol transport pathway is believed to provide protection against atherosclerosis. In reverse cholesterol transport, peripheral tissues (e.g., vessel-wall macrophages) remove their excess cholesterol through the ATP-binding cassette transporter 1 (ABCA1) to poorly lipidated apolipoprotein A-I, forming pre--HDL. Lecithin–cholesterol acyltransferase then esterifies free cholesterol to cholesteryl esters, converting pre--HDL to mature spherical -HDL (see Figure).

View larger version (71K): [in this window] [in a new window]   Figure. Schematic Model of Reverse Cholesterol Transport . . . [Full Text of this Article]

 

Source Information

From the National Heart, Lung, and Blood Institute, Bethesda, Md.

This article has been cited by other articles:

• Savransky, V., Bevans, S., Nanayakkara, A., Li, J., Smith, P. L., Torbenson, M. S., Polotsky, V. Y. (2007). Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G871-G877 [Abstract] [Full Text]  
• Yvan-Charvet, L., Matsuura, F., Wang, N., Bamberger, M. J., Nguyen, T., Rinninger, F., Jiang, X.-C., Shear, C. L., Tall, A. R. (2007). Inhibition of Cholesteryl Ester Transfer Protein by Torcetrapib Modestly Increases Macrophage Cholesterol Efflux to HDL. Arterioscler. Thromb. Vasc. Bio. 27: 1132-1138 [Abstract] [Full Text]  
• Modest, G. A. (2007). Lack of Evidence for Recommended Low-Density Lipoprotein Cholesterol Treatment Targets. ANN INTERN MED 146: 614-614 [Full Text]  
• Eichinger, S., Pecheniuk, N. M., Hron, G., Deguchi, H., Schemper, M., Kyrle, P. A., Griffin, J. H. (2007). High-Density Lipoprotein and the Risk of Recurrent Venous Thromboembolism. Circulation 115: 1609-1614 [Abstract] [Full Text]  
• Sanossian, N., Saver, J. L., Navab, M., Ovbiagele, B. (2007). High-Density Lipoprotein Cholesterol: An Emerging Target for Stroke Treatment. Stroke 38: 1104-1109 [Abstract] [Full Text]  
• Li, J., Savransky, V., Nanayakkara, A., Smith, P. L., O'Donnell, C. P., Polotsky, V. Y. (2007). Hyperlipidemia and lipid peroxidation are dependent on the severity of chronic intermittent hypoxia. J. Appl. Physiol. 102: 557-563 [Abstract] [Full Text]  
• Fazio, S., Linton, M. F. (2006). Sorting Out The Complexities of Reverse Cholesterol Transport: CETP Polymorphisms, HDL, and Coronary Disease.. J. Clin. Endocrinol. Metab. 91: 3273-3275 [Full Text]  
• Kontush, A., Chapman, M. J. (2006). Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis. Pharmacol. Rev. 58: 342-374 [Abstract] [Full Text]  
• Briand, M., Lemieux, I., Dumesnil, J. G., Mathieu, P., Cartier, A., Despres, J.-P., Arsenault, M., Couet, J., Pibarot, P. (2006). Metabolic Syndrome Negatively Influences Disease Progression and Prognosis in Aortic Stenosis. J Am Coll Cardiol 47: 2229-2236 [Abstract] [Full Text]  
• Authors/Task Force Members, , Fox, K., Garcia, M. A. A., Ardissino, D., Buszman, P., Camici, P. G., Crea, F., Daly, C., De Backer, G., Hjemdahl, P., Lopez-Sendon, J., Marco, J., Morais, J., Pepper, J., Sechtem, U., Simoons, M., Thygesen, K., ESC Committee for Practice Guidelines (CPG), , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, J., Dean, V., Deckers, J., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J., Zamorano, J. L., Document Reviewers, , Zamorano, J. L, Andreotti, F., Becher, H., Dietz, R., Fraser, A., Gray, H., Antolin, R. A. H., Huber, K., Kremastinos, D. T., Maseri, A., Nesser, H.-J., Pasierski, T., Sigwart, U., Tubaro, M., Weis, M. (2006). Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 27: 1341-1381 [Full Text]  
• Lee, C.-H., Plutzky, J. (2006). Liver X Receptor Activation and High-Density Lipoprotein Biology: A Reversal of Fortune?. Circulation 113: 5-8 [Full Text]  
• Ansell, B. J., Watson, K. E., Fogelman, A. M., Navab, M., Fonarow, G. C. (2005). High-Density Lipoprotein Function: Recent Advances. J Am Coll Cardiol 46: 1792-1798 [Abstract] [Full Text]  
• Giugliano, R. P., Braunwald, E. (2005). The Year in Non--ST-Segment Elevation Acute Coronary Syndromes. J Am Coll Cardiol 46: 906-919 [Full Text]  
• Forrester, J. S., Makkar, R., Shah, P.K. (2005). Increasing High-Density Lipoprotein Cholesterol in Dyslipidemia by Cholesteryl Ester Transfer Protein Inhibition: An Update for Clinicians. Circulation 111: 1847-1854 [Abstract] [Full Text]